Medscape | Idelalisib Combo Rings Bells in Relapsed CLL Medscape That drug is idelalisib, a PI3 kinase delta isoform-specific inhibitor. The study by Furman and colleagues was a randomized, placebo-controlled, double-blind trial of rituximab plus placebo vs rituximab plus the oral drug idelalisib in patients with ... |
